EXEL · CIK 939767
What Exelixis, Inc. told the SEC could break it.
Exelixis's defining risk is single-franchise dependence: substantially all of its product revenue and gross margin come from one drug, cabozantinib (CABOMETYX) — its cost of goods is mainly a 3% royalty on all net sales of cabozantinib-containing products — so its results ride on that franchise's demand, competition and patent life. Outside the US, including major EU markets and Japan, pricing and reimbursement of its partner-commercialized products face significant government control and cost-control pressure that could squeeze its royalty revenue. Domestically, it sells principally through a limited set of specialty distributors and pharmacies, concentrating its channel and collection risk in those intermediaries.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- single-franchise dependence on cabozantinib (CABOMETYX)high
Substantially all of Exelixis's product revenue and gross margin derive from cabozantinib (CABOMETYX) — its cost of goods sold consists primarily of a 3% royalty payable on all net sales of any product containing cabozantinib — leaving the company heavily exposed to that single franchise's demand, competition and patent life.
“Cost of goods sold is related to our product revenues and consists primarily of a 3 % royalty we are required to pay on all net sales of any product containing cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.”
SEC filing →As of 2026
Regulatory & policy
- ex-US government pricing/reimbursement control (EU, Japan)medium
Outside the US — including major EU markets and Japan — pricing and reimbursement of prescription pharmaceuticals is subject to significant governmental control and cost-control initiatives, which could delay marketing and pressure prices of Exelixis's (partner-commercialized) products, reducing royalty revenue.
“Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to significant governmental control.”
SEC filing →As of 2026
Customer concentration
- US sales channeled through specialty distributors/pharmacieslow
Exelixis sells its products principally to a limited set of specialty distributors and specialty pharmacy providers (which resell to providers/patients), concentrating its US product-revenue collection and channel risk in those intermediaries.
“We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments due to Royalty Pharma have also increased.”
Cited →Ipsen S.A.
“As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments due to Royalty Pharma have also increased.”
Cited →“As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments due to Royalty Pharma have also increased.”
Cited →
Its suppliers
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch